belinostat + carboplatin + paclitaxel + bevacizumab

This is a four-drug combination regimen consisting of belinostat, carboplatin, paclitaxel, and bevacizumab. - **Belinostat** is a histone deacetylase (HDAC) inhibitor that modulates gene expression by altering chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. - **Paclitaxel** is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination has been explored primarily in the treatment of advanced or recurrent epithelial ovarian cancer and other solid tumors. The addition of belinostat to the standard carboplatin-paclitaxel-bevacizumab regimen represents an investigational approach aiming to enhance antitumor efficacy through epigenetic modulation alongside cytotoxic chemotherapy and antiangiogenic therapy[1][2][3].

Other names

BelCaP plus bevacizumab